With the identification of the PKC isozymes PRKCA, PRKCB, PRKCE, PRKCH and PRKCQ as targets of miR-34a-5p, we contribute to understand the mechanisms of regulation of PKC isozymes and substantiate the potential of miR-34a as pharmacological target for cancer treatment as shown in various preclinical studies [52–55] and a clinical trial (NCT01829971). This evidence concerns the gene PRKCH and cancer.